BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 19153271)

  • 1. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
    Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
    Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiological follow-up in patients with Fabry disease].
    Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
    G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement.
    Lobo T; Morgan J; Bjorksten A; Nicholls K; Grigg L; Centra E; Becker G
    Intern Med J; 2008 Jun; 38(6):407-14. PubMed ID: 18613897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease.
    Weidemann F; Breunig F; Beer M; Sandstede J; Störk S; Voelker W; Ertl G; Knoll A; Wanner C; Strotmann JM
    Eur Heart J; 2005 Jun; 26(12):1221-7. PubMed ID: 15728649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of late gadolinium enhancement on cardiovascular magnetic resonance in patients with hypertrophic cardiomyopathy].
    Dumont CA; Monserrat L; Soler R; Rodríguez E; Fernández X; Peteiro J; Bouzas B; Piñón P; Castro-Beiras A
    Rev Esp Cardiol; 2007 Jan; 60(1):15-23. PubMed ID: 17288951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac challenges in patients with Fabry disease.
    Weidemann F; Linhart A; Monserrat L; Strotmann J
    Int J Cardiol; 2010 May; 141(1):3-10. PubMed ID: 19720409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging.
    Popović ZB; Kwon DH; Mishra M; Buakhamsri A; Greenberg NL; Thamilarasan M; Flamm SD; Thomas JD; Lever HM; Desai MY
    J Am Soc Echocardiogr; 2008 Dec; 21(12):1299-305. PubMed ID: 19041572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
    Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis.
    van Dockum WG; Kuijer JP; Götte MJ; Ten Cate FJ; Ten Berg JM; Beek AM; Twisk JW; Marcus JT; Visser CA; van Rossum AC
    Eur Heart J; 2006 Dec; 27(23):2833-9. PubMed ID: 17098761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tei index in fabry disease.
    Niemann M; Breunig F; Beer M; Hu K; Liu D; Emmert A; Herrmann S; Ertl G; Wanner C; Takenaka T; Tei C; Weidemann F
    J Am Soc Echocardiogr; 2011 Sep; 24(9):1026-32. PubMed ID: 21719255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
    Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
    Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.
    Niemann M; Herrmann S; Hu K; Breunig F; Strotmann J; Beer M; Machann W; Voelker W; Ertl G; Wanner C; Weidemann F
    JACC Cardiovasc Imaging; 2011 Jun; 4(6):592-601. PubMed ID: 21679893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection and quantification of myocardial fibrosis in hypertrophic cardiomyopathy by contrast-enhanced cardiovascular magnetic resonance].
    Pujadas S; Carreras F; Arrastio X; Leta R; Vila M; Subirana MT; Bayés-Genís A; Pons-Lladó G
    Rev Esp Cardiol; 2007 Jan; 60(1):10-4. PubMed ID: 17288950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadolinium-enhanced cardiovascular magnetic resonance and exercise capacity in hypertrophic cardiomyopathy.
    Romero-Puche A; Marín F; González-Carrillo J; García-Honrubia A; Climent V; Feliu E; Ruiz-Espejo F; Payá E; Gimeno-Blanes JR; de la Morena G; Valdés-Chavarri M
    Rev Esp Cardiol; 2008 Aug; 61(8):853-60. PubMed ID: 18684368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
    Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
    Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabry disease with aortic regurgitation.
    Choi S; Seo H; Park M; Kim J; Hwang S; Kwon K; Her K; Won Y
    Ann Thorac Surg; 2009 Feb; 87(2):625-8. PubMed ID: 19161799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease.
    Krämer J; Niemann M; Liu D; Hu K; Machann W; Beer M; Wanner C; Ertl G; Weidemann F
    Eur Heart J; 2013 Jun; 34(21):1587-96. PubMed ID: 23520186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of quantitative analysis of remote myocardial fibrosis with delayed-enhancement magnetic resonance imaging to predict outcomes after surgical ventricular restoration for ischemic cardiomyopathy.
    Takeda K; Matsumiya G; Matsue H; Hamada S; Sakaki M; Sakaguchi T; Fujita T; Sawa Y
    J Thorac Cardiovasc Surg; 2008 Dec; 136(6):1514-21. PubMed ID: 19114200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.